Jay Brad­ner’s NI­BR ex­it sets off a suc­ces­sion plan at Mer­ck; Dyne and Mor­phoSys fill ma­jor R&D roles

→ In the Big Phar­ma world, com­pa­nies like J&J and Mer­ck have ex­pe­ri­enced a pro­nounced sea change in lead­er­ship over a two-year pe­ri­od, and you can be­gin to say the same at No­var­tis, which dis­missed head of de­vel­op­ment John Tsai and head of on­col­o­gy Su­sanne Schaf­fert as part of CEO Vas Narasimhan’s wide-rang­ing re­struc­tur­ing plan. The next shoe to drop is Jay Brad­ner, the pres­i­dent of the No­var­tis In­sti­tutes for Bio­Med­ical Re­search, who is leav­ing his post on Hal­loween and pass­ing the ba­ton to Fiona Mar­shall, Mer­ck’s SVP and glob­al head of dis­cov­ery sci­ences, pre­clin­i­cal de­vel­op­ment and trans­la­tion­al med­i­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER